Objectively Assessed Physiological, Physical, and Cognitive Function Along with Patient-reported Outcomes During the First 2 Years of Alemtuzumab Treatment in Multiple Sclerosis: a Prospective Observational Study

Overview

Journal J Neurol

Specialty Neurology

Date 2022 Apr 28

PMID 35482080

Authors

Lars G Hvid

Egon Stenager

Ulrik Dalgas

Affiliations

Soon will be listed here.

Abstract

Introduction: In persons with multiple sclerosis (pwMS), little evidence exist on the effects of Alemtuzumab on physiological, physical, and cognitive function along with patient-reported outcomes, despite these domains are being rated as highly important. Therefore, our purpose was to perform a prospective observational study to examine these outlined outcomes during the first two years of Alemtuzumab treatment in pwMS.

Methods: In n = 17 relapsing-remitting pwMS, physiological function [body composition; bone mineral content; muscle strength; aerobic capacity], physical function [6-min walk test (6MWT, primary outcome); timed 25 ft walk test (T25FWT); six spot step test (SSST); 9-step stair ascend (9SSA); timed up and go test (TUG); 5 × sit to stand test (5STS)], cognitive function [selective reminding test (SRT); symbol digit modalities test (SDMT)], and patient-reported outcomes [multiple sclerosis impact scale-29 (MSIS29); 12-item multiple sclerosis walking scale (MSWS12); modified fatigue impact scale (MFIS); hospital anxiety and depression scale (HADS)] were assessed prior to Alemtuzumab treatment initiation as well as 3, 6, 12, and 24 months into the treatment.

Results: Improvements were observed at 24-month follow-up in T25FWT (+ 8%), SSST (+ 10%), SDMT (+ 5.2 points, 53% improved more than the clinical cut-off score) and SRT, whereas the primary outcome 6MWT, and all other remaining outcomes, remained stable throughout the Alemtuzumab treatment period.

Conclusion: The present findings suggest that Alemtuzumab treatment in relapsing-remitting pwMS can improve certain domains of physical function (short distance walking) and cognitive function (processing speed, memory), and furthermore stabilize physiological and physical function along with patient-reported outcomes.

Trial Registration: Registered at clinicaltrials.gov: NCT03806387.

Citing Articles

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana J, Eichau S, Casanova B, Rodriguez E, Pato A, Forner M J Patient Rep Outcomes. 2024; 8(1):148.

PMID: 39692844 PMC: 11655941. DOI: 10.1186/s41687-024-00822-9.

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.

Sandgren S, Novakova L, Nordin A, Axelsson M, Malmestrom C, Zetterberg H Front Neurol. 2023; 14:1265354.

PMID: 37808497 PMC: 10551138. DOI: 10.3389/fneur.2023.1265354.

The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician's review.

Kania K, Ambrosius W, Kozubski W, Kalinowska-Lyszczarz A Front Neurol. 2023; 14:1222574.

PMID: 37503514 PMC: 10368887. DOI: 10.3389/fneur.2023.1222574.

Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.

Woelfle T, Bourguignon L, Lorscheider J, Kappos L, Naegelin Y, Jutzeler C J Med Internet Res. 2023; 25:e44428.

PMID: 37498655 PMC: 10415952. DOI: 10.2196/44428.

References

Reich D, Lucchinetti C, Calabresi P . Multiple Sclerosis. N Engl J Med. 2018; 378(2):169-180. PMC: 6942519. DOI: 10.1056/NEJMra1401483. View

Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A . Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurol Sci. 2015; 37(2):165-79. DOI: 10.1007/s10072-015-2400-1. View

Rocca M, Comi G, Filippi M . The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. Front Neurol. 2017; 8:433. PMC: 5591328. DOI: 10.3389/fneur.2017.00433. View

Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P . Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2015; 23(2):282-9. DOI: 10.1111/ene.12715. View

Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F . Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2016; 23(9):1258-1267. DOI: 10.1177/1352458516674367. View

LaRocca N . Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011; 4(3):189-201. DOI: 10.2165/11591150-000000000-00000. View

Hvid L, Feys P, Baert I, Kalron A, Dalgas U . Accelerated Trajectories of Walking Capacity Across the Adult Life Span in Persons With Multiple Sclerosis: An Underrecognized Challenge. Neurorehabil Neural Repair. 2020; 34(4):360-369. DOI: 10.1177/1545968320907074. View

DeLuca G, Yates R, Beale H, Morrow S . Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. Brain Pathol. 2014; 25(1):79-98. PMC: 8029470. DOI: 10.1111/bpa.12220. View

Kister I, Bacon T, Chamot E, Salter A, Cutter G, Kalina J . Natural history of multiple sclerosis symptoms. Int J MS Care. 2014; 15(3):146-58. PMC: 3883021. DOI: 10.7224/1537-2073.2012-053. View

10.

Kalron A, Achiron A, Dvir Z . Muscular and gait abnormalities in persons with early onset multiple sclerosis. J Neurol Phys Ther. 2011; 35(4):164-9. DOI: 10.1097/NPT.0b013e31823801f4. View

11.

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G . Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016; 9 Suppl 1:S5-S48. DOI: 10.1016/j.msard.2016.07.003. View

12.

Green R, Cutter G, Friendly M, Kister I . Which symptoms contribute the most to patients' perception of health in multiple sclerosis?. Mult Scler J Exp Transl Clin. 2017; 3(3):2055217317728301. PMC: 5588807. DOI: 10.1177/2055217317728301. View

13.

Heesen C, Haase R, Melzig S, Poettgen J, Berghoff M, Paul F . Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2017; 137(3):356-362. DOI: 10.1111/ane.12881. View

14.

McGinley M, Goldschmidt C, Rae-Grant A . Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021; 325(8):765-779. DOI: 10.1001/jama.2020.26858. View

15.

Torkildsen O, Myhr K, Bo L . Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2015; 23 Suppl 1:18-27. PMC: 4670697. DOI: 10.1111/ene.12883. View

16.

Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M . Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021; 14:17562864211019574. PMC: 8170278. DOI: 10.1177/17562864211019574. View

17.

Landmeyer N, Burkner P, Wiendl H, Ruck T, Hartung H, Holling H . Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. Neurology. 2020; 94(22):e2373-e2383. DOI: 10.1212/WNL.0000000000009522. View

18.

Lanzillo R, Sparaco M, Lavorgna L, Carmisciano L, Signoriello E, Signori A . A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurol Sci. 2020; 41(11):3235-3241. DOI: 10.1007/s10072-020-04367-9. View

19.

Nowinski C, Miller D, Cella D . Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials. Neurotherapeutics. 2017; 14(4):934-944. PMC: 5722775. DOI: 10.1007/s13311-017-0571-6. View

20.

Dalgas U, Langeskov-Christensen M, Stenager E, Riemenschneider M, Hvid L . Exercise as Medicine in Multiple Sclerosis-Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives. Curr Neurol Neurosci Rep. 2019; 19(11):88. DOI: 10.1007/s11910-019-1002-3. View